
Biosecurity & clinical development @PopVaxIndia | views are my own https://teapawt.net/t.co/OUImYWcpQz
Joined May 2026
- Tweets65
- Following354
- Followers117
- Likes307
Hannah Herzig retweeted
UPDATE: Excited to announce our first-ever BiTS Accelerator cohort focused on biosecurity.
We see a big gap between funding interest (by govts and funders) and well-vetted ideas and the doers to drive them.
These fellows can start to fill that critical gap.
We're excited to announce our sixth Big if True Science (BiTS) Accelerator cohort - this one focused on biosecurity.
Big ideas in biosecurity need more than funding. They need program design that makes them executable. That’s the gap BiTS is built to close. Supported by @coeff_giving, our 12 BiTS Biosecurity Fellows are working to defend against catastrophic risks from engineered pathogens.
Find out more: renaissancephilanthropy.org/…
Meet the Cohort ↓
1/13
Hannah Herzig retweeted
Gene therapies can be used to cure autoimmune diseases, including lupus. I find this really exciting.
I first heard about this while reporting an article about CRISPR medicines. I was asking people what they thought the big “blockbuster” would be for CRISPR therapies, and most people talked about CAR-T for cancer, and how instead of engineering T cells ex vivo, we could use lipid nanoparticles to reprogram them inside the body and lower costs. But Jacob Witten mentioned a study from Germany where patients with lupus were treated with CAR-T cells that attack their own B cells, and went into complete remission.
Lupus is an autoimmune disease, meaning the immune system attacks the body itself. About 1 in 1,400 people in the US are thought to have it, and it’s about 9x more common in women than men. It can cause hair loss, weird sun sensitivity, mouth ulcers, and a bunch of other symptoms. It’s a strange disease that we still don’t fully understand.
So in a 2024 paper, researchers in Germany treated 15 patients with three autoimmune diseases: eight with lupus, three with inflammatory myositis, and four with systemic sclerosis.
They took T cells out of the patients and engineered them with a receptor that recognizes CD19, a protein on B cells. They gave the patients chemotherapy to suppress their immune cells, then reinfused the engineered T cells. Those cells started killing B cells. And it worked really well! Patients went 112 days, on average, without detectable B cells in their blood. All eight lupus patients went into remission, too. Resetting their B cells seemed, somehow, to get rid of the disease. (Wiping out B cells isn’t a good thing in itself, obviously, because it can increase the risk of infections.)
In 2026, the same group studied 24 patients; nine of ten with lupus were in remission after six months. These studies weren't randomized or blinded, though. So now, randomized trials are comparing CAR-T cells against antibodies that also attack CD19 on B cells. It’s not yet clear whether CAR-T works better, but I suspect it will. It’s incredible how fast this is all happening: the first CAR-T experiment for lupus (in mice) was published in 2019, and the first human case report only came out in 2021.
These studies also used ex vivo CAR-T, where you take cells out of the patient, engineer them, and reinfuse them. But this is slow and costly, and you could do this instead with in vivo CAR-T, using lipid nanoparticles to deliver RNA encoding the anti-CD19 receptor directly to T cells without removing them from the body. The RNA would disappear after a while, so the T cells wouldn’t have to remain permanently modified. In a small 2025 study from China, researchers did this in five patients with lupus. The treatment wiped out B cells and reduced disease symptoms, though it’s still too early to say how well this will work.
Hannah Herzig retweeted
Unironically, it is so good that biology is cool now. Everyone should be rooting for AI to cure all disease. Stop speculating about whether it will or will not happen and ask yourself what you personally can do to make it happen. Then do it
Hannah Herzig retweeted
Yash is 34 and has pancreatic cancer. When he found out, it was already at Stage 4.
@PopVaxIndia is developing a personalised cancer vaccine for Yash, and they're open sourcing his tumour sequencing data + their vaccine design.
Check out the repo here: github.com/popvax/yash
We’re making a personalized cancer vaccine for Yash, a 34 year-old pancreatic cancer patient, in the open with his consent.
We want external experts to review our design and make their own contributions before we manufacture it at the RNA Foundry.
RNAFoundry.com/yash
Hannah Herzig retweeted
Replying to @sohamsankaran @PopVaxIndia
The wonderful @jajoosam -- the man in the video -- built our vaccine design pipeline, and is looking forward to input from scientists across the world! Take a look and make a pull request at github.com/popvax/yash
Hannah Herzig retweeted
We’re making a personalized cancer vaccine for Yash, a 34 year-old pancreatic cancer patient, in the open with his consent.
We want external experts to review our design and make their own contributions before we manufacture it at the RNA Foundry.
RNAFoundry.com/yash
Hannah Herzig retweeted
AI-designed viruses are coming, and our team @PopVaxIndia is building the Immune Engine to produce medicines against these threats within 4 weeks from sequencing. We're basing this work, led by @hcherzig, in London because of the UK's prescient vision in AI safety & biosecurity.
Just as @ukgov were the first government to establish an AI safety & security lab @AISecurityInst, they are now the first government to set up a dedicated organisation to combat the biosecurity risks created by generative AI, which require a different approach than natural threats.
We’ve been talking with the team building the AI Biosecurity Lab over the past few weeks, and we’re confident that they’re building an institution that is capable of meeting the enormous challenges that lie ahead. We look forward to working with them to help secure the world against the threat of AI-enabled bioweapons.
Replying to @KanishkaNarayan
2/7 We're launching a £165m National AI Biosecurity Initiative, including £100m for a world-first AI Biosecurity Lab.
This will harness British scientific expertise and latest AI to detect biological threats and protect people from emerging risks.
As with our @AISecurityInst, I want the new AIBL to lead the world in capability.
Hannah Herzig retweeted
Check out the AI Biosecurity Lab we are building.
UK gov announcement: gov.uk/government/news/intro…
BBC coverage: bbc.co.uk/news/articles/cqdj…
FT coverage: ft.com/content/e4481867-fecc…
Bloomberg coverage: bloomberg.com/news/articles/…
Replying to @KanishkaNarayan
2/7 We're launching a £165m National AI Biosecurity Initiative, including £100m for a world-first AI Biosecurity Lab.
This will harness British scientific expertise and latest AI to detect biological threats and protect people from emerging risks.
As with our @AISecurityInst, I want the new AIBL to lead the world in capability.
Hannah Herzig retweeted
Kudos to @sohamsankaran for this cutting edge endeavour
Hannah Herzig retweeted
We've spent the last 30 months building the physical infrastructure to develop personalized medicines.
Now, we deploy: in the next year, we will manufacture 100+ mRNA cancer vaccines - each purpose built for a single person.
RNAFoundry.com
Hannah Herzig retweeted
Grateful to @NPR for the chance to talk about how stress and infections like COVID can stir dormant viruses in our bodies, and what that may mean for our immune system. Still much to learn, and I’m thankful to my team and colleagues for their work 🎧 npr.org/2026/10/23/nx-s1-598…
Hannah Herzig retweeted
The thing I always loved most about @restofworld articles was the focus on the ordinary people behind the global tech headlines.
Incredible storytelling over the years.
Re-sharing one of my all-time favorites from @violazhouyi and @NilChristopher: restofworld.org/2023/foxconn…
Hannah Herzig retweeted
This is playing with fire.
Minks and ferrets have such humanlike lung cells that they’re the standard for testing human flu transmission. (Cows aren’t!)
An H5N1 epidemic raging in a mink farm is basically the plot for Dr. Evil tries to spark a pandemic. Luck isn’t a plan.
Hannah Herzig retweeted
I’m seeing a lot of uninformed takes, like this one, about cell simulation feasibility. I wanted to contribute some facts.
Alphafold works for predicting a subset of static structures (not how a protein structure changes shape under forces) on 1) well-ordered regions (not intrinsically disordered regions or long flexible loops) and 2) on proteins with plenty of evolutionary relatives (no orphan proteins).
Alphafold solved this subset of static structure prediction with a dataset that took 50 years (PDB; 1971 to ~2020) to collect. It did not solve protein dynamics or how proteins fold into their shapes. Those remain unsolved.
Cell simulation is vastly more complex and data hungry than any of this. Exact cell simulation means solving quantum equations for every atom and is totally intractable. But all approximations rely on - and are bottlenecked by - data, not compute.
So the extrapolation from “alphafold worked” to “therefore cell simulation is feasible” assumes far too much.
If you had an exponential amount of compute you could solve simulate biology exactly and wouldn't need to run any experiments.
Some of you will think "of course, but that's an unrealistic assumption" and others will think "no, you need experiments even with that much compute. That's just How It's Done".
You would of course need evaluations once you have a solution, but you don't in principle need experiments to find it: Experiments are a way to save compute, dating from a time when it was much more expensive.
And I think the presentation is exponential but real systems aren't irreducibly exponential. AlphaFold worked, after all.
Hannah Herzig retweeted
PopVax's first vaccine entered a Phase I clinical trial on August 31. We're following this up with an ambitious pipeline of vaccines (HCV, TB, Strep A, rabies) and cancer therapeutics (liver & pancreatic cancer). Come help us develop new medicines to save 1 million lives each year! Here are some key open positions:
Principal Scientist - Analytical Method Development (jobs.popvax.com/30208) and Senior Scientist - HPLC Method Development (jobs.popvax.com/41508): We design millions of new molecules – proteins, RNA, LNPs, and more. Your job is to figure out how to characterize them at high-throughput without sacrificing rigour, repeatability, and robustness, as well as to help make those methods GMP-grade as part of the handover to QC. We intend to take new medicines into clinical trials in weeks, not years, so we need to build adaptable analytical platforms, not bespoke methods that work for only one molecule. We strongly prefer candidates with the ability to write code to build automated data analysis pipelines for their methods – LLM-generated code is fine as long as you are able to comprehensively validate the logic and output of the pipelines.
Head of Quality Control (jobs.popvax.com/41525) – We manufacture our own clinical doses at the RNA Foundry, and every analytical method we develop for a new molecule eventually has to become a validated QC method. You’ll lead the team that tests every batch to international GMP standards, take on method transfers from analytical development, and build a QC function that can keep pace with a pipeline aiming to reach the clinic in weeks, not years.
Junior Scientist - Vaccine Immunology (jobs.popvax.com/37003) – Our vaccine programs halt or advance on the immunogenicity data that comes back from animal and organoid studies. You’ll run the assays that produce that data – ELISAs, pseudovirus neutralization, and bacterial growth-inhibition assays – and coordinate animal studies with our internal teams and CROs, following each study from plan to samples to result. We prefer candidates who can write code for routine data analysis.
Head of Legal (jobs.popvax.com/41524) – Our first vaccine was manufactured in India, was filled into vials in the US, and has now entered a clinical trial in Australia. We work with dozens of counterparties – funders, governments, universities, CROs, and suppliers – with more added each week. You’ll own the day-to-day of our Indian legal work, from contracts to compliance to labour law, work with the legal teams supporting our UK and Australian operations, and make sure paperwork is never the bottleneck between our new medicines and the clinic.
Chief of Staff to the Chief Science Officer: Our CSO needs a partner who can take experimental planning and coordination off his plate so that he can spend more time thinking hard about our thorniest problems. You will turn complex scientific hypotheses into clear executable plans, coordinate with scientists to see each experiment through, and analyze the data to help plan the next round of iteration. You’ll need a strong scientific background, a sharp eye for detail, and boundless energy to keep ambitious scientific work moving. To apply, email dhruv [at] popvax [dot] com with a human-written explanation of why you’re the best person for the job.
If none of these are a good fit, take a look popvax.com/jobs or email us at work [at] popvax [dot] com.
On August 31, the first two participants were injected with @PopVaxIndia’s first fridge-stable RNA vaccine candidate in a Phase I clinical trial in Australia. We built this vaccine at our RNA Foundry in Hyderabad – from computational design to GMP manufacturing. Here's how:
Hannah Herzig retweeted
This is exactly what @hcherzig and I are working on @PopVaxIndia across the UK, the US, and India!
Read more here: chronicles.popvax.com/p/apoc…
In my lab, we use AI to discover new antibiotics and other medical countermeasures. But the same technologies could also make it easier to create biological threats.
In my @washingtonpost op-ed, I argue that U.S. biodefense must keep pace with AI. Building the capacity to protect people takes years. We cannot afford to wait for a crisis.
Read: washingtonpost.com/opinions/…
Hannah Herzig retweeted
P.S. AI protein design gets the headlines. Whether the thing in the tube is actually what you designed gets decided by analytical methods. My team at @PopVaxIndia is hiring an analytical scientist for protein characterisation (SEC-HPLC) jobs.popvax.com/41532
On August 31, the first two participants were injected with @PopVaxIndia’s first fridge-stable RNA vaccine candidate in a Phase I clinical trial in Australia. We built this vaccine at our RNA Foundry in Hyderabad – from computational design to GMP manufacturing. Here's how:
Pfizer's original COVID vaccine needed a freezer at about -70C, which many clinics do not have. On August 31, the first volunteers in Melbourne got an mRNA vaccine that stays stable for at least 9 months in an ordinary fridge.
It was built by @PopVaxIndia, a Hyderabad team that started in late 2021 in a shared lab smaller than a parking spot and now designs vaccines with AI.
The shot delivers mRNA instructions in a tiny fat bubble. Your cells read them and build a harmless fake virus, a ball covered in copies of the coronavirus spike tip. Immune cells react far more strongly to many copies packed together, and in mice the ball produced over 50x the virus-blocking antibodies of the spike tip alone.
The mouse and fridge results come straight from PopVax and have not been peer-reviewed. The trial in 36 volunteers is testing safety.
Gene editing and CAR-T, which reprograms immune cells to attack disease, already reach patients in trials inside the same kind of fat bubble. A small team in India building its own is how those medicines reach people outside rich countries.
Huge congrats @sohamsankaran and team. Watch the film.
On August 31, the first two participants were injected with @PopVaxIndia’s first fridge-stable RNA vaccine candidate in a Phase I clinical trial in Australia. We built this vaccine at our RNA Foundry in Hyderabad – from computational design to GMP manufacturing. Here's how:
Hannah Herzig retweeted
Just so people understand the significance of this news from India (because Hyderabad-based PopVax is a company you should be tracking):
Many mRNA COVID vaccines out there have two flaws: 1. They need very cold freezers to stay potent, and 2. They stop being effective when the virus mutates.
PopVax made a COVID mRNA vaccine that can stay in a normal fridge for months without expiring, and it's designed to remain effective even when the virus changes.
Their vaccine (PVX-001) was entirely designed and manufactured in India, and they plan to open source the design so that other teams can build on their work.
After these human trials, PopVax will replicate their methodology across other vaccines + cancer therapies. Their goal is to leverage AI to make vaccines/therapies which are faster and cheaper to produce, more resilient, and more effective than anything else out there.
On August 31, the first two participants were injected with @PopVaxIndia’s first fridge-stable RNA vaccine candidate in a Phase I clinical trial in Australia. We built this vaccine at our RNA Foundry in Hyderabad – from computational design to GMP manufacturing. Here's how:


























